Christopher E.M. Griffiths
Christopher E.M. Griffiths
Professor of Dermatology, University of Manchester
Bestätigte E-Mail-Adresse bei manchester.ac.uk
Titel
Zitiert von
Zitiert von
Jahr
Pathogenesis and clinical features of psoriasis
CEM Griffiths, JNWN Barker
The Lancet 370 (9583), 263-271, 2007
18722007
Secukinumab in plaque psoriasis—results of two phase 3 trials
RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ...
New England Journal of Medicine 371 (4), 326-338, 2014
15512014
Global epidemiology of psoriasis: a systematic review of incidence and prevalence
R Parisi, DPM Symmons, CEM Griffiths, DM Ashcroft
Journal of Investigative Dermatology 133 (2), 377-385, 2013
15422013
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich, FO Nestle, K Papp, JP Ortonne, R Evans, C Guzzo, S Li, ...
The Lancet 366 (9494), 1367-1374, 2005
11612005
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley, GG Krueger, CEM Griffiths
Annals of the rheumatic diseases 64 (suppl 2), ii18-ii23, 2005
9832005
Rook's textbook of dermatology
T Burns, S Breathnach, N Cox, C Griffiths
John Wiley & Sons, 2008
9792008
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
CEM Griffiths, BE Strober, P van de Kerkhof, V Ho, R Fidelus-Gort, ...
New England Journal of Medicine 362 (2), 118-128, 2010
8992010
Keratinocytes as initiators of inflammation
JNWN Barker, CEM Griffiths, BJ Nickoloff, RS Mitra, VM Dixit
The Lancet 337 (8735), 211-214, 1991
8681991
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
A Strange, F Capon, CCA Spencer, J Knight, ME Weale, MH Allen, ...
Nature genetics 42 (11), 985, 2010
8652010
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, ...
8132009
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
LC Tsoi, SL Spain, J Knight, E Ellinghaus, PE Stuart, F Capon, J Ding, ...
Nature genetics 44 (12), 1341-1348, 2012
7832012
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ...
British Journal of Dermatology 152 (6), 1304-1312, 2005
7602005
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U Mrowietz, K Kragballe, K Reich, P Spuls, CEM Griffiths, A Nast, J Franke, ...
Archives of dermatological research 303 (1), 1-10, 2011
7262011
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
CEM Griffiths, K Reich, M Lebwohl, P van de Kerkhof, C Paul, A Menter, ...
The Lancet 386 (9993), 541-551, 2015
6362015
Cyclosporine improves psoriasis in a double-blind study
CN Ellis, DC Gorsulowsky, TA Hamilton, JK Billings, MD Brown, ...
Jama 256 (22), 3110-3116, 1986
6301986
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn, MGS Dunnill, A Shetty, JJ Bowden, JDL Williams, ...
Gut 55 (4), 505-509, 2006
6212006
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.
BJ Nickoloff, GD Karabin, JN Barker, CE Griffiths, V Sarma, RS Mitra, ...
The American journal of pathology 138 (1), 129, 1991
5561991
Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor
CEM Griffiths, JJ Voorhees, BJ Nickoloff
Journal of the American Academy of Dermatology 20 (4), 617-629, 1989
5471989
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
CH Smith, AV Anstey, J Barker, AD Burden, RJG Chalmers, DA Chandler, ...
British Journal of Dermatology 161 (5), 987-1019, 2009
5292009
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded …
A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ...
The Lancet 389 (10086), 2287-2303, 2017
5262017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20